Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3942-3947

  Kanter, Julie ^a   Khan, Samina Y ^b   Kelher, Marguerite ^b   Gore, Lia ^e   Silliman, Christopher C ^b,c,d  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Bonfils Blood Center

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR; THROMBOCYTE CONCENTRATE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANGIOGENIC PROTEIN; CARCINOGEN; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR AB; PLATELET-DERIVED GROWTH FACTOR AB; SIGNAL PEPTIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

APHERESIS; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; STORAGE; SUPERNATANT; THROMBOCYTE TRANSFUSION; BLOOD; BLOOD STORAGE; IMMUNOLOGY; METABOLISM; THROMBOCYTOPHERESIS;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANTIBODIES, MONOCLONAL; BLOOD PRESERVATION; CARCINOGENS; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PLATELET-DERIVED GROWTH FACTOR; PLATELETPHERESIS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 52449095974     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4824     Document Type: Article

References (78)

1. Technical manual, 15th ed. Bethesda : American Association of Blood Banks, 2005.
2. AuBuchon JP, Taylor H, Holme S, Nelson E. In vitro and in vivo evaluation of leukoreduced platelets stored for 7 days in CLX containers. Transfusion 2005;45:1356-61.
3. AuBuchon JP, Herschel L, Roger J. Further evaluation of a new standard of efficacy for stored platelets Transfusion 2005;45:1143-50.
4. Fang CT, Chambers LA, Kennedy J, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience. 2004. Transfusion 2005;45:1845-52.
5. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004;91:4-15.
6. Zimmermann R, Jakubietz R, Jakubietz M, et al. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion 2001;41:1217-24
7. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81:1241 -57.
8. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;13:1845-57.
9. Sledge GW, Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002;29:104-10.
10. Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001;285:1592-601.
11. Hillyer CD, Lankford KV, Roback JD, GillespieTW, Silberstein LE. Transfusion of the HIV-seropositive patient : immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Transfus Med Rev 1999;13:1 -17.
12. Opelz G.Terasaki PI. Poor kidney-transplant survival in recipients with frozen-blood transfusions or no transfusions. Lancet 1974;2:696-8.
13. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978;299:799-803
14. Unander AM, Lindholm A. Transfusions of leukocyte-rich erythrocyte concentrates: a successful treatment in selected cases of habitual abortion. Am J Obstet Gynecol 1986;154:516-20.
15. Blajchman MA, Bardossy L, Carmen R, Sastry A, Singal DP. Allogeneic blood transfusion-induced enhancement of tumor growth : two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993;81:1880-2.
16. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 1994;118:371-9.
17. Blumberg N, Heal JM. Transfusion immunomodulation. In: Anderson KC, Ness PM. Scientific basis of transfusion medicine. 2nd ed. Philadelphia : W B. Saunders; 2000. p. 427-43.
18. Kaliss N, Snell GD. The effects of injections of lyophilized normal and neoplastic mouse tissues on the growth of tumor homiotransplants in mice. Cancer Res 1951;11:122-6.
19. Parrott NR, Lennard TW, Proud G, et al. Blood transfusion and surgery : the effect on growth of a syngeneic sarcoma. Ann R Coll Surg Engl 1990;72:77-81.
20. Waymack JP, Fernandes G, Yurt RW, et al. Effect of blood transfusions on immune function. Part VI. Effect on immunologic response to tumor. Surgery 1990;108:172-7
21. Blumberg N, Heal JM, Rowe JM. A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440]. BMC Blood Disord 2004;4:6.
22. Silliman CC, Dickey WO, Paterson AJ, et al Analysis of the priming activity of lipids generated during routine storage of platelet concentrates. Transfusion 1996;36:133-9
23. Vesilind GW, Simpson MB, Shifman MA, Colman RE, Kao KJ. Evaluation of a centrifugal blood cell processor for washing platelet concentrates. Transfusion 1988;28:46-51.
24. McLaughlin NJ, Banerjee A, Kelher MR, et al. Platelet-activating factor-induced clathrin-mediated endocytosis requires β-arrestin-1 recruitment and activation of the p38 MAPK signalosome at the plasma membrane for actin bundle formation. J Immunol 2006;176:7039-50.
25. Bentas W, Beecken WD, Glienke W, Binder J, Schuldes H. Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors. Urol Res 2003;30:390-3.
26. Czarkowska-Paczek B, Bartiomiejczyk I, Przybylski J. The serum levels of growth factors: PDGF,TGF-β and VEGF are increased after strenuous physical exercise. J Physiol Pharmacol 2006;57:189-97.
27. Efimova EA, Glanemann M, Nussler AK, et al. Changes in serum levels of growth factors in healthy individuals after living related liver donation. Transplant Proc 2005;37:1074-5.
28. Filiberti R, Marroni P, Neri M, et al. Serum PDGF-AB in pleural mesothelioma. Tumour Biol 2005;26:221-6
29. Naumnik B, Borawski J, Pawlak K, Mysliwiec M. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-β1 during haemodialysis: a cross-over study. Nephrol Dial Transplant 2007;22:1690-6.
30. Tabone MD, Landman-Parker J, Arcil B, et al. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res 2001;7:538-43.
31. Akerblom B, Lindahl TL, Larsson A. ADP activation induces bFGF binding to platelets in vitro. Ups J Med Sci 2002;107:165-71.
32. Ferns GA, Motani AS, Anggard EE. The insulin-like growth factors : their putative role in atherogenesis. Artery 1991;18:197-225.
33. Handin Rl. Blood platelets and the vessel wall. In: Nathan DG, Orkin SH, Ginsburg D, Look AT. Nathan and Oski's hematology of infancy and childhood. 6th ed. Philadelphia: Saunders; 2003. p. 1457-74.
34. Hwang DL, Latus LJ, Lev-Ran A. Effects of platelet-contained growth factors (PDGF, EGF, IGF-I, TGF-β) on DNA synthesis in porcine aortic smooth muscle cells in culture. Exp Cell Res1992;200:358-60.
35. Miyazono K, Takaku F. Platelet-derived growth factors. Blood Rev1989;3:269-76.
36. Cianciolo G, Stefoni S, Zanchelli F, et al. PDGF-AB release during and after haemodialysis procedure. Nephrol Dial Transplant 1999;14:2413-9.
37. Buck SA, Kickler TS, McGuire M, Braine HG, Ness PM. The utility of platelet washing using an automated procedure for severe platelet allergic reactions. Transfusion 1987;27:391 -3.
38. Kalmin ND, Brown DJ. Platelet washing with a blood cell processor. Transfusion 1982;22:125-7.
39. Ringwald J, Althoff F, Zimmermann R, et al. Washing platelets with new additive solutions : aspects on the in vitro quality after 48 hours of storage. Transfusion 2006;46:236-43.
40. Rudderow D, Soslau G. Permanent lesions of stored platelets correlate to pH and cell count while reversible lesions do not. Proc Soc Exp Biol Med 1998;217:219-27.
41. Schoenfeld H, Muhm M, Doepfmer U, Exadaktylos A, Radtke H. Platelet activity in washed platelet concentrates. Anesth Analg 2004;99:17-20.
42. Silvergleid AJ, Hafleigh EB, Harabin MA, Wolf RM, Grumet FC. Clinical value of washed-platelet concentrates in patients with non-hemolytic transfusion reactions. Transfusion 1977;17:33-7.
43. Foss B, Ulvestad E, Bruserud O. Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia : PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur J Haematol 2001;67:267-78.
44. Homsi J, Daud Al. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007;14:285-94.
45. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma Cancer 2005 103:1800-9
46. de Labarthe A, Rousselot P. Huguet-Rigal F, et al Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the GRAAPH-2003 study. Blood 2007:109 1408-13.
47. Yanada M, NaoeT. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice Leuk Lymphoma 2006;47:1747-53.
48. Lee SB, Kolquist KA, Nichols K, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet 1997;17:309 13.
49. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-9.
50. Bond M, Bernstein ML, Pappo A, et al A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study Pediatr Blood Cancer 2008;50:254-8.
51. Fernando NH, Hurwitz HI Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003;30:39-50.
52. Pintucci G, Froum S, Pinnell J. Mignatti P, Rafii S. Green D. Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), Thromb Haemost 2002;88:834-42.
53. Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies Integr Cancer Ther 2005;4:315-21.
54. Wartiovaara U, Salven P, Mikkola H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998;80:171-5.
55. Ben Arush MW, Schenzer P, Maurice S, et al. Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. Pediatr Hematol Oncol 2005;22:513-24.
56. Ben Arush MW, Ben BA. Maurice S, Livne E. Serum VEGF as a significant marker of treatment response in Hodgkin lymphoma. Pediatr Hematol Oncol 2007,24 111-5.
57. Jakowlew SB. Transforming growth factor-β. in cancer and metastasis. Cancer Metastasis Rev 2006;25:435-57.
58. Steiner MS, Barrack ER Transforming growth factor-β1 overproduction in prostate cancer : effects on growth in vivo and in vitro. Mol Endocrinol 1992. 6:15-25.
59. Wikstrom P, Bergh A, Damber JE. Transforming growth factor-β1 and prostate cancer. Scand J Urol Nephrol 2000;34:85-94
60. Zhou L, Leung BS. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors α and β1 Biochim Biophys Acta 1992;1180:130-6.
61. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer J Clin Oncol 2005.23: 2078-93
62. Banovic T, MacDonald KP, Morris ES, et al. TGF-βin allogeneic stem cell transplantation : friend or foe? Blood 2005;106:2206-14.
63. Billottet C, Janji B, Thiery JP, Jouanneau J. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2. Oncogene 2002;21:8128-39.
64. Chodorowska G, Tomczyk M, Glowacka A. Basicfibroblast growth factor (b-FGF) - its biological role in physiologic and pathologic conditions. Ann Univ Mariae Curie Sklodowska [Med] 2004;59:286-91.
65. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41.
66. Okunieff P, Fenton BM, Zhang L, et al. Fibroblast growth factors (FGFS) increase breast tumor growth rate, metastases, blood flow, and oxygenation without significant change in vascular density. Adv Exp Med Biol 2003;530:593-601.
67. Bieker R, Padro T, Kramer J, et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res 2003;63:7241-6.
68. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist 2004;9 Suppl 1:36-42.
69. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006:24:3354-60.
70. Mancuso A, Sternberg CN. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice? Crit Rev Oncol Hematol 2005;55:67-81.
71. Moses MA, Harper J, Fernandez CA. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep 2004;6:42-8.
72. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
73. Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007;13:5341-7.
74. George JN, Saucerman S. Platelet IgG, IgA, IgM, albumin: correlation of platelet and plasma concentrations in normal subjects and in patients with ITP or dysproteinemia. Blood 1988;72:362-5.
75. Handagama PJ, George JN, Shuman MA, McEver RP, Bainton DF. Incorporation of a circulating protein into megakaryocyte and platelet granules. Proc Natl Acad Sci U S A 1987;84:861 -5.
76. Handagama PJ, Shuman MA, Bainton DF. Incorporation of intravenously injected albumin, immunoglobulin G, fibrinogen in guinea pig megakaryocyte granules. J Clin Invest 1989;84:73-82.
77. Klouche M, Klinger MH, Kuhnel W.Wilhelm D. Endocytosis, storage, and release of IgE by human platelets: differences in patients with type I allergy and nonatopic subjects. J Allergy Clin Immunol 1997;100:235-41.
78. Suehiro Y, Veljkovic DK, Fuller N, et al. Endocytosis and storage of plasma factor V by human megakaryocytes. Thromb Haemost 2005;94:585-92.